Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hassel

Showing results (121-130 of 322) with videos related to

Pageof 33
Sort By:
BMC Cancer|July 17, 2013
Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trialG Habl, K Potthoff, M F Haefner, et al.
The British Journal of Dermatology|April 11, 2016
Anti-programmed cell death-1 therapy in nonmelanoma skin cancerJ K Winkler, R Schneiderbauer, C Bender, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten MelanomKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanomaKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Diet-dependent toxicity of ipilimumab in metastatic melanomaP Majenka, M Hoffmann, I Rötzer, et al.
Oncoimmunology|May 4, 2016
Vemurafenib and ipilimumab: A promising combination? Results of a case seriesJessica C Hassel, Sophia B Lee, Frank Meiss, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2021
Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot studyMartin Salzmann, Georgi Tosev, Melanie Heck, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patientsSophia B Strobel, Devayani Machiraju, Melanie Wiecken, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 8, 2012
Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centersBernhard Homey, Peter Arne Gerber, Andreas Wollenberg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 12, 2017
Acute heart failure as a result of granulomatous myocarditis: case report on a patient with metastatic melanoma treated with dabrafenib and trametinibJ K Winkler, K Buder-Bakhaya, E Ellert, et al.
Pageof 33

Showing results (121-130 of 322) with videos related to

Sort By:
Pageof 33
BMC Cancer|July 17, 2013
Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trialG Habl, K Potthoff, M F Haefner, et al.
The British Journal of Dermatology|April 11, 2016
Anti-programmed cell death-1 therapy in nonmelanoma skin cancerJ K Winkler, R Schneiderbauer, C Bender, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten MelanomKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanomaKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Diet-dependent toxicity of ipilimumab in metastatic melanomaP Majenka, M Hoffmann, I Rötzer, et al.
Oncoimmunology|May 4, 2016
Vemurafenib and ipilimumab: A promising combination? Results of a case seriesJessica C Hassel, Sophia B Lee, Frank Meiss, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2021
Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot studyMartin Salzmann, Georgi Tosev, Melanie Heck, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patientsSophia B Strobel, Devayani Machiraju, Melanie Wiecken, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 8, 2012
Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centersBernhard Homey, Peter Arne Gerber, Andreas Wollenberg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 12, 2017
Acute heart failure as a result of granulomatous myocarditis: case report on a patient with metastatic melanoma treated with dabrafenib and trametinibJ K Winkler, K Buder-Bakhaya, E Ellert, et al.
Pageof 33